Arecor Therapeutics PLC · LSE:AREC
Arecor Therapeutics — H1 2021 Earnings Presentation
21 slides from Arecor Therapeutics's earnings presentation, Sep 23, 2021

Slide 1: Advancing today's therapies to enable healthier lives
Advancing today’s therapies to enable healthier lives Interim Results 23 September 2021 www.arecor.com

Slide 2: Legal notice
Legal notice This Presentation does not constitute, or form part of, nor is it intended to communicate, any offer, invitation, inducement or recommendation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any shares in the Company in any jurisdiction nor shall it, or

Slide 3: Introduction
01 Introduction Page 2 Arecor 2021 | Confidential

Slide 4: Presentation Team
Presentation Team Dr Sarah Howell Susan Lowther Chief Executive Officer Chief Financial Officer Page 3 Arecor 2021 | Confidential

Slide 5: Company summary
Company summary Driving better healthcare through the transformation of today’s therapies Arestat™ proprietary technology Clinical company developing proprietary platform pipeline of enhanced medicines Recent IPO • Enhances properties of existing • Diabetes - favourable clinical data + near proceeds

Slide 6: Operational Highlights
Operational Highlights Driving better healthcare through the transformation of today’s therapies Proprietary Pipeline • Positive results from AT278-102 Phase I clinical study • IND clearance for AT247 3-day insulin pump clinical study in US • Awarded £2.8m Innovate UK grant to support PhII clinical

Slide 7: A broad portfolio of de-risked and innovative assets
A broad portfolio of de-risked and innovative assets Portfolio of de-risked in-house and partnered programmes Product Area Research Preclinical Phase 1 Phase 2 Phase 3 Est launch1 Market size AT247 Diabetes 2025 Arecor Development AT278 Diabetes 2025 ~$6.4B2 AT299 Diabetes 2028 Clinical Development

Slide 8: Expanding portfolio of partnerships with new collaborations signed in 2021
Expanding portfolio of partnerships with 3 new collaborations signed so far in 2021 Revenue generating collaborations offering future license potential Exclusive formulation study Exclusive formulation study Exclusive formulation collaboration with collaboration with Lilly collaboration with Par Ste

Slide 9: Arecor's proprietary development pipeline
02 Arecor’s proprietary development pipeline Page 8 Arecor 2021 | Confidential

Slide 10: Diabetes: Arecor's first therapeutic franchise
Diabetes: Arecor’s first therapeutic franchise A major worldwide health issue with significant unmet needs in diabetes care AT247 Ultra rapid Blood glucose Arecor’s goal is to improve acting insulin with potential to treatment outcomes for be the best-in-class 180 mg/dl patients requiring insulin, F

Slide 11: AT247: Improved profile vs current gold standard treatments
AT247: Improved profile vs current gold standard treatments Superiority for onset of appearance and exposure during 120min after dosing compared with Fiasp® and NovoRapid® Phase I clinical study¹ results Successfully AT247 vs Fiasp® met all primary (p<0.05) endpoints with best-in-class 2-fold increa

Slide 12: AT247: Improved profile vs current gold standard treatments
AT247: Improved profile vs current gold standard treatments Superiority for early insulin action during 120min after dosing compared with Fiasp® and NovoRapid® Phase I clinical study¹ results Successfully AT247 vs Fiasp® met all primary (p<0.05) endpoints with best-in-class 9 mins faster onset of ac

Slide 13: AT278: The challenge and patient need
AT278: The challenge and patient need Creating a disrupter insulin Challenge Need Increasing insulin concentration = slower insulin action Superior insulin for severe insulin resistant patients who Faster insulins = improved blood glucose control need to administer large daily doses (>200 U/da

Slide 14: AT278 500 U/mL: Positive results from first Phase I clinical study
AT278 500 U/mL: Positive results from first Phase I clinical study; significantly accelerated PK/PD compared to 100 U/mL NovoRapid® Potential to be the first concentrated ultra-rapid insulin product available to patients Study Design AT278 potential to be first • Double-blind, randomized, two-way cr

Slide 15: Diabetes franchise – Key upcoming milestones
Diabetes franchise – Key upcoming milestones Develop to clinical value inflexion point prior to licensing Research Pre-Clinical Phase 1 Phase 2 Upcoming Milestone AT247 Ultra Rapid US Phase 1 insulin pump study initiation – Late 2021 Acting Insulin AT278 Ultra AT278-104 clinical study planning in pr

Slide 16: Financials, outlook and newsflow
03 Financials, outlook and newsflow Page 15 Arecor 2021 | Confidential

Slide 17: Financial Highlights
Financial Highlights Driving better healthcare through the transformation of today’s therapies Successful AIM IPO • Raised £20m new investment at a share price of 226p • Market cap capitalisation of £62.5m at Admission Revenue • Revenue of £0.5m (H1 2020: £0.8m, including £0.3m milestone) R&D • Inve

Slide 18: Key financials
Key financials Six months Six months Year ended to 30 Jun to 30 June 31 Dec 2020 Highlights 2021 2020 Revenue Formulation development revenue of £0.5m in line with prior period Revenue £0.5m £0.8m £1.7m 2020: included £0.3m milestone Other income - £0.4m £0.4m Other Income Total income £0.5m £1.2m £

Slide 19: Arecor: Focused on execution and delivery
Arecor: Focused on execution and delivery Key upcoming milestones 2020 2021 2022 • 3 new license agreements: • £2.8m Innovate UK grant award • Clinical results from diabetes Hikma x 2, Inhibrx franchise • Successful AIM IPO raising • Positive AT247 Phase I £20m • Expand specialty hospital clinical d

Slide 20: Highlights to date and what's next
Highlights to date and what’s next…. Driving better healthcare through the transformation of today’s therapies Highlights to date • Significant clinical development progress within diabetes franchise • AT278-102 positive Phase I clinical results • AT247-103 IND clearance from FDA • Awarded £2.8m Inn

Slide 21: Thank you
>< Arecor Thank you
Source: Internet Archive copy of arecor.com
More decks from Arecor Therapeutics PLC
H1 2026 Earnings Presentation21 slides · Oct 12, 2026
Investor Presentation (October 2026)30 slides · October 2026
Investor Presentation (June 2026)30 slides · June 2026
FY2025 Earnings Presentation34 slides · Apr 23, 2026
FY2025 Earnings Presentation34 slides · Apr 13, 2026
FY2024 Earnings Presentation21 slides · Apr 22, 2025